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Introduction {#sec1}
============

Primitive hematopoiesis initiates in the yolk sac with a transient wave of primitive erythroid progenitors; however, definitive hematopoiesis occurs via a temporally and spatially dynamic pattern ([@bib32]). The definitive hematopoiesis firstly generates erythroid with adult-type features but does not produce hematopoietic stem cells (HSCs) in the yolk sac ([@bib1]). The second wave of definitive hematopoiesis is marked by the emergence of HSCs originated from hemogenic endothelium (HE) in the aorto-gonad-mesonephros (AGM) region of the embryo through the endothelial-to-hematopoietic transition (EHT) ([@bib2], [@bib16], [@bib27], [@bib41], [@bib43]), while more pre-HSCs generated from AGM region move to the fetal liver (FL) and then acquire a mature HSC property ([@bib37]). Developmental hematopoiesis has been mainly studied in mouse models, but early human hematopoiesis is poorly understood. The establishment of human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs) led to the development of models that are ideal to explore early hematopoiesis in humans ([@bib9], [@bib42], [@bib44], [@bib49]). Several recent studies reported the development of hPSC-derived early mesodermal precursors into mature hematopoietic stem/progenitor cells (HSPCs) *in vitro* ([@bib31], [@bib39]). The latter cells can be traced as CD34^+^CD43^+^CD45^+^CD90^+^CD38^--^ cells; these surface markers are typical of human HSCs emerging in AGM and FL *in vivo* ([@bib36]). Although phenotypically similar to their adult-type counterparts in AGM, hPSC-derived HSPCs generated *in vitro* cannot reconstitute hematopoiesis in NOG-SCID mice ([@bib31]). Gene manipulation has been performed to enhance the HSC property of hPSC-derived HS-like cells. Overexpression of medial HOXA genes prolongs the maintenance of hESC-derived HSPCs but does not confer self-renewal in hESC-derived HSPCs ([@bib11]). A more recent study showed that hESC-derived CD34^+^KDR^+^CD43^−^GPA^--^ HE cells with a definitive hematopoietic potential reconstitute hematopoiesis in NOG-SCID mice when transfected with five transcription factors (*HOXA9*, *ERG*, *RORA*, *SOX4*, and *MYB*) ([@bib40]). However, this previous study did not purify HSCs *in vitro*. It remains challenging to generate hPSC-derived HSCs *in vitro*.

The transcription factor *GATA2* plays a unique role in the development, maintenance, and quiescence of HSCs, particularly in the AGM. In mouse embryos, *Gata2* is expressed in lateral plate mesoderm (LPM)-, AGM-, and FL-derived HSCs ([@bib28], [@bib29]). Knockout (KO^−/--^) of *Gata2* blocks the development of murine HSCs in the AGM region. Deletion of a *cis* element located 9.5 kb downstream of the *Gata2* promoter (^+^9.5) in mice decreases *Gata2* expression in HE in AGM, and abrogates the EHT ([@bib13]). RNA sequencing (RNA-seq) demonstrated that *GATA2* and other HSC-specific genes are upregulated in human CD34^+^CD45^+^CD38^--^ (34^+^45^+^38^--^) HSPCs derived from HE-5TF cells ([@bib40]). *GATA2*-knockout hESCs exhibit marked defects in the EHT and conversion into HSPCs, while specification of HE is unaffected ([@bib19]). By contrast, GATA2/eGFP^+^ hESCs give rise to an increased number of HSPCs ([@bib15]). During the development of hPSCs into HSPCs *in vitro*, expression of *GATA2* is upregulated along with the KDR^+^APLNR^+^CD34^−^CD43^--^ early mesodermal precursors ([@bib6]). On the other hand, overexpression of GATA2 (GATA2-OE) hampers, rather than enhances, HSC activity in human cord blood (CB)-derived CD34^+^ HSCs by inducing cell-cycle arrest at the G0/G1 phase ([@bib45]). Thus, GATA2 has diverse effects on the early stages of mesodermal hematopoietic lineage specification, the EHT, and maintenance of HSCs. It is unknown how GATA2 elicits these effects and at what level GATA2 influences the cell fate decision.

We previously reported an efficient coculture system with AGM-S3 cells that facilitates definitive hematopoiesis of hPSCs *in vitro* ([@bib25], [@bib48]). In the current study, we established hESCs in which GATA2-OE was induced by treatment with doxycycline (Dox) using a PiggyBac (PB)-based Tet-on system, and the functional role of GATA2 in the early stages of hematopoiesis was analyzed. Our data revealed that GATA2 functions at different time points to initiate, enhance, and maintain definitive hematopoiesis of hESCs by regulating the cell cycle. Specifically, GATA2 exerts dual functions by promoting the generation of definitive hematopoietic progenitors before and after the EHT and arresting CD34^+^CD45^+^CD90^+^CD38^--^ (34^+^45^+^90^+^38^--^) HS-like cells in a quiescent state.

Results {#sec2}
=======

Generation of an hESC Line with Inducible GATA2 Overexpression {#sec2.1}
--------------------------------------------------------------

To explore the function of GATA2 in hematopoietic fate determination, we generated H1-GFP-GATA2 hESCs (G2/hESCs) in which exogenous expression of GATA2 was induced on treatment with Dox using a previously described PB-based Tet-on system ([Figure 1](#fig1){ref-type="fig"}A) ([@bib5]). In the absence of Dox, G2/hESCs expressed key stemness-specific markers, such as SOX2, OCT4, and SSEA4 ([Figure 1](#fig1){ref-type="fig"}B). PCR analysis verified that the coding sequence (CDS) of *GATA2* was integrated into the genome of G2/hESCs ([Figure 1](#fig1){ref-type="fig"}C). G2/hESCs could be repeatedly passaged and retained a hESC phenotype without Dox ([Figure 1](#fig1){ref-type="fig"}D). Western blotting and qRT-PCR showed increased expression of GATA2 in G2/hESCs and AGM-S3 cocultures (G2/hESC cocultures) with increased concentration of Dox from 0 to 4 μg/mL ([Figures 1](#fig1){ref-type="fig"}E and 1F). Treatment with Dox (1μg/mL) increased the percentage of GFP^+^ cells and the mRNA expression of *GATA2* in G2/hESCs from 0 to 96 h ([Figures 1](#fig1){ref-type="fig"}D, 1G, and 1H). There were three hESC clones used for the experiments with 1, 2, and 4 copies of transgene detected by qPCR, respectively ([Figure 1](#fig1){ref-type="fig"}I) ([@bib7]); The three hESC clones showed increased expression of GATA2 mRNA and protein with increased copies of transgene detected by qRT-PCR and western blotting ([Figures 1](#fig1){ref-type="fig"}I and 1J). These results demonstrated that G2/hESCs were pluripotent and had a normal phenotype, that the CDS of *GATA2* was integrated into the genome of these cells, and that treatment with Dox-induced GATA2-OE from 0 to 4 μg/mL.Figure 1Generation and Analysis of G2/hESCs(A) Schematic illustration of the PB Tet-on inducible expression system and the strategy used to establish G2/hESCs.(B) Immunofluorescence staining of pluripotency markers in G2/hESCs. Scale bars, 50 μm.(C) Confirmation of homologous recombination in G2/hESCs by PCR. Genomic DNA was isolated from wild-type hESCs, GFP-expressing hESCs, and G2/hESCs.(D) Fluorescence and phase-contrast images of G2/hESCs cultured in mTeSR1 medium containing and lacking Dox. Scale bars, 50 μm.(E) Western blotting and qRT-PCR analysis of GATA2 expression in various concentrations of Dox (0--8 μg/mL)-treated G2/hESCs and AGM-S3 cocultures (G2/hESC cocultures) on day 7.(F) qRT-PCR analysis of *GATA2* expression in various concentrations of Dox (0--8 μg/mL)-treated G2/hESCs and AGM-S3 cocultures (G2/hESC cocultures) on day 7.(G) Flow cytometric analysis of the percentage of GFP^+^ cells among Dox-treated G2/hESCs.(H) qRT-PCR analysis of *GATA2* expression in G2/hESCs treated with Dox for 0--96 h.(I and J) Western blotting (I) and qRT-PCR (J) analysis of GATA2 expression in G2/hESC cocultures on day7 derived from three different G2/hESC clones with various transgene copy number.Error bars represent mean ± SD of samples from at least three independent experiments. NS, not significant; ^∗^p \< 0.05, ^∗∗^p \< 0.01.

GATA2 Overexpression in hESCs Promotes Definitive Hematopoiesis {#sec2.2}
---------------------------------------------------------------

We firstly elucidated the hematopoietic cells in the H1 hESCs and AGM-S3 cocultures ([Figure 2](#fig2){ref-type="fig"}A). KDR^+^ cells, which are mesodermal precursors of hematopoietic and endothelial lineages, gradually express CD34 during human embryonic development ([@bib8]). In H1 hESCs and AGM-S3 coculture, the KDR^+^CD34^−^CD43^--^ (K^+^34^--^43^--^) cells mainly expressed mesodermal proteins and genes compared with the KDR^+^CD34^+^CD43^--^ (K^+^34^+^43^--^) cells ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). CD43 was previously used as a marker of hematopoietic progenitors in cocultures of hPSCs and OP9 cells ([@bib47]). CD34^+^CD43^+^ (34^+^43^+^) cells expressed markers of hematopoietic progenitors and upregulated hematopoietic genes compared with CD34^+^CD43^--^ (34^+^43^--^) cells ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1D). In cocultures of H1 hESCs and AGM-S3 cells, the former cells differentiate into (APLNR^+^KDR^−/+^CD34^--^, A^+^K^−/+^34^--^) mesodermal progenitors (CD34^+^CD43^--^, 34^+^43^--^) endothelial cells, and (CD34^+^CD43^+^CD45^−/+^, 34^+^43^+^45^−/+^) hematopoietic progenitors in a stepwise manner ([Figures S1](#mmc1){ref-type="supplementary-material"}E and S1F), as occurs in other hematopoietic systems ([@bib38]). *GATA2* expression was upregulated during hematopoiesis ([Figure S1](#mmc1){ref-type="supplementary-material"}G). *GATA2* expression in 34^+^43^+^ and 34^+^45^+^ hematopoietic cells derived from H1 hESCs was comparable with that in human CB-derived CD34^+^ cells ([Figure S1](#mmc1){ref-type="supplementary-material"}H). These data demonstrate that the AGM-S3 stromal cell line efficiently induced hematopoietic differentiation of hESCs and simulated the early stages of hematopoiesis ([Figure S1](#mmc1){ref-type="supplementary-material"}I) ([@bib25], [@bib48]). Expression of *GATA2* increased during the development of 34^+^43^+^45^−/+^ hematopoietic cells from hESCs.Figure 2GATA2-OE in hESCs Promotes Definitive Hematopoiesis(A) Experimental scheme to study the stage-wise effect of GATA2 on hematopoietic development.(B) Absolute numbers of 34^+^43^+^, 34^+^43^+^45^+^, and 34^+^45^+^90^+^38^−^ cells in untreated and Dox-treated G2/hESC cocultures on days 2--22.(C) Colony formation by total cells collected from untreated and Dox-treated G2/hESC cocultures on days 14, 20, and 22.(D) Formation of BFU-E and Mix colonies by total cells collected from untreated and Dox-treated G2/hESC cocultures on day 14.(E) Percentages and absolute numbers of 34^+^43^+^45^--^, 34^+^43^+^45^+^, and 34^+^45^+^90^+^38^--^ cells in untreated and Dox-treated G2/hESC cocultures on day 14.(F) Flow cytometric analysis of 34^+^43^+^45^+^ cells in untreated and Dox-treated G2/hESC cocultures on day 14.(G) Immunofluorescence staining of CD34 and CD43 in untreated and Dox-treated G2/hESC cocultures on day 14. Scale bars, 100 μm.Error bars represent mean ± SD of samples from at least three independent experiments. NS, not significant; ^∗^p \< 0.05, ^∗∗^p \< 0.01.

We further evaluated the role of GATA2 in hematopoiesis by three different culture systems. The hematopoietic efficiency in the promotion of 34^+^45^+^90^+^38^--^ cells was improved in AGM-S3 coculture than in OP9 and stromal cell-free culture ([Figure S1](#mmc1){ref-type="supplementary-material"}J). Transition of 34^+^K^+^43^--^ cells into 34^+^43^+^ cells was predominantly enhanced in AGM-S3 cocultures ([Figure S1](#mmc1){ref-type="supplementary-material"}K). A comparable increase of *GATA2* expression was paralleled to the increase of Dox dose from 0 to 4 μg/mL, accompanying by an enhanced promotion of 34^+^43^+^ cells in G2/hESC cocultures ([Figure S2](#mmc1){ref-type="supplementary-material"}A). We found 1 μg/mL Dox was enough to trigger *GATA2* overexpression, and this dose was used in further experiments. We found that all three hESC lines with different transgene copy numbers demonstrated similar efficacy in promoting hematopoiesis; however, there was a slight difference in enhancement ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C). On the other hand, the vector control hESCs showed no difference in differentiation with and without Dox ([Figure S2](#mmc1){ref-type="supplementary-material"}C). To identify barriers to the generation of hematopoietic cells from GATA2-overexpressing hESCs, we analyzed the proportion of hematopoietic cells among G2/hESC cocultures at days 6, 10, and 14, when Dox treatment was initiated at different time points ([Figure S2](#mmc1){ref-type="supplementary-material"}D). Addition of Dox from day 2 until the day of collection promoted the development of K^+^34^--^43^--^, 34^+^K^+^43^--^, 34^+^43^+^, and 34^+^43^+^45^+^ cells ([Figure S2](#mmc1){ref-type="supplementary-material"}D).

We next evaluated the effect GATA2-OE on hematopoiesis from day 2 to 22. The increased level of *GATA2* expression mainly relied on exogenous *GATA2* expression both at the various times of differentiation and in the 34^+^43^+^-sorted cells with Dox ([Figures S2](#mmc1){ref-type="supplementary-material"}E and S2F). The total cell number was not markedly affected (data not shown). GATA2-OE prolonged the growth of 34^+^43^+^45^−/+^ and 34^+^45^+^90^+^38^--^ cells in cocultures over 22 days ([Figures 2](#fig2){ref-type="fig"}B and [S2](#mmc1){ref-type="supplementary-material"}G). Moreover, GATA2-OE increased the generation of 34^+^45^+^90^+^38^--^ HS-like cells by more than 4.8-fold in cocultures. Total cells collected from Dox-treated cocultures on days 14, 20, and 22 formed an increased number of colonies, which coincided with the increase in hematopoietic cells; however, more colonies were observed when Dox was removed during the colony-formation assay ([Figure 2](#fig2){ref-type="fig"}C). BFU-E and Mix colonies recovered when Dox was removed in cloned cultures ([Figure 2](#fig2){ref-type="fig"}D).

Fluorescence-activated cell sorting (FACS) analysis demonstrated that the levels of 34^+^43^+^45^--^ cells (pre-HSPCs), 34^+^43^+^45^+^ cells (HSPCs), and 34^+^45^+^90^+^38^--^ cells (HS-like cells) were increased in Dox-treated cocultures at day 14 ([Figures 2](#fig2){ref-type="fig"}E and 2F). Immunofluorescence staining of CD34 and CD43 showed that dense networks of blood vessels and many hematopoietic cells formed in Dox-treated cocultures on day 14 ([Figure 2](#fig2){ref-type="fig"}G).These data demonstrate that GATA2-OE promotes the generation of hematopoietic cells and prolongs the colony-forming unit (CFU) potential of cocultured cells.

GATA2 Overexpression Promotes Definitive Hematopoiesis via Differentiation of hESC-Derived Mesodermal KDR^+^CD34^--^ (K^+^34^--^) Cells and the EHT {#sec2.3}
---------------------------------------------------------------------------------------------------------------------------------------------------

The percentage and number of early mesodermal cells with an A^+^K^--^34^--^ phenotype did not markedly differ. However, the number of K^+^34^--^ cells, including definitive mesodermal cells with an A^+^K^+^34^--^ phenotype, was higher in Dox-treated cocultures than in untreated cocultures ([Figures 3](#fig3){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}A). Expression of primitive streak (PS) and LPM genes increased on Dox treatment ([Figure 3](#fig3){ref-type="fig"}B). Thus, GATA2-OE promoted the generation of hESC-derived mesodermal K^+^34^--^ cells, including A^+^K^+^34^--^ and A^−^K^+^34^--^ cells.Figure 3GATA2-OE Promotes Development of 34^+^43^+^45^+^ HSPCs via Mesodermal Differentiation and the EHT(A) Absolute numbers of A^+^K^--^34^--^, A^+^K^+^34^--^, and A^−^K^+^34^--^ cells in untreated and Dox-treated G2/hESC cocultures on days 0--10.(B) Heatmap of expression of genes associated with the development of germ layers in untreated and Dox-treated G2/hESC cocultures on day 4. PL, pluripotency genes; PS, primitive streak genes; LPM, lateral plate mesoderm genes; PXM, paraxial mesoderm genes; IM, intermediate mesoderm genes; EN, endodermal genes; EC, ectodermal genes.(C) Experimental scheme. 34^+^K^+^43^−^ cells and 34^+^43^+^45^--/+^cells were isolated from coculture at days 6 and 14, respectively, then recultured for an additional 14 days onto AGM-S3-coated plates with and without Dox.(D) Flow cytometric analysis of K^+^34^+^43^--^ cells sorted from G2/hESC cocultures on day 6.(E) The K^+^34^+^43^--^ cells sorted from G2/hESC cocultures on day 6 were recultured on AGM-S3 cells with and without Dox. The numbers of K^+/--^34^+^43^+^ and 34^+^43^+^45^−/+^ cells were determined by flow cytometry.(F) Microscopic analysis and immunofluorescence staining of CD43 in K^+^34^+^43^--^ cells cocultured with AGM-S3 cells with and without Dox for 7 days. Scale bars, 50 μm.(G) 34^+^43^+^45^--^ and 34^+^43^+^45^+^ cells were sorted from G2/hESC cocultures on day 14 and recultured on AGM-S3 cells for 14 days with and without Dox. The numbers of 34^+^43^+^45^+^ cells were determined by flow cytometry.(H) qRT-PCR analysis of relative *GATA2* expression in siRNA-transfected cells from day 4 G2/hESC cocultures.(I) The absolute number of 34^+^43^+^ cells in cocultures treated with si-GATA2 (20 nM) or control siRNA for 2 and 4 days.(J) Heatmap of gene expression in 34^+^K^+^43^--^ cells derived from untreated and Dox-treated G2/hESC cocultures on day 6. M, mesodermal genes; EG, endothelial genes; Hem, hematopoietic genes.Error bars represent mean ± SD of samples from at least three independent experiments. NS, not significant; ^∗^p \< 0.05, ^∗∗^p \< 0.01.

The increase in 34^+^43^+^ cells in cocultures on GATA2-OE may be because of the promotion of EHT and after EHT. To determine whether GATA2-OE promotes EHT, 34^+^K^+^43^--^ cells were sorted from cocultures on day 6 and recultured on AGM-S3 cells in the presence or absence of Dox ([Figures 3](#fig3){ref-type="fig"}C and 3D). 34^+^K^+^43^--^ cells gave rise to more 34^+^43^+^ cells, including 34^+^43^+^K^+/--^ and 34^+^43^+^45^−/+^ cells, in the presence of Dox ([Figures 3](#fig3){ref-type="fig"}E and [S3](#mmc1){ref-type="supplementary-material"}B). Immunofluorescence staining revealed that 34^+^K^+^43^--^ cells gave rise to more CD43^+^ cells on GATA2-OE for 7 days ([Figure 3](#fig3){ref-type="fig"}F). To investigate the effect of GATA2-OE on expansion of 34^+^43^+^45^--^ and 34^+^43^+^45^+^ cells after the EHT, both cell populations were sorted from cocultures on day 14 and recultured on AGM-S3 cells ([Figure 3](#fig3){ref-type="fig"}C). GATA2-OE did not markedly affect the expansion of 34^+^43^+^45^+^ cells ([Figure 3](#fig3){ref-type="fig"}G).

To further elucidate the effect of GATA2-OE on EHT, cocultures on day 4, which lacked emerging CD43^+^ cells, were transfected with GATA2-targeting (si-GATA2: GUCCAAGAAGAGCAAGAAATT) or control siRNA (si-N:UUCUCCGAACGUGUCACGUTT) ([Figure S3](#mmc1){ref-type="supplementary-material"}C). Transfection of 20 nM si-GATA2 significantly decreased endogenous *GATA2* expression by more than 42.3% ([Figure 3](#fig3){ref-type="fig"}H). Downregulation of *GATA2* decreased the emergence of 34^+^43^+^ cells ([Figures 3](#fig3){ref-type="fig"}I and [S3](#mmc1){ref-type="supplementary-material"}C).

Relative gene expression profiles differed between 34^+^K^+^43^--^ cells sorted from untreated and Dox-treated cocultures on day 6. Hematopoietic genes were upregulated in 34^+^K^+^43^--^ cells on GATA2-OE ([Figure 3](#fig3){ref-type="fig"}J).

These data suggest that GATA2-OE promotes the generation of 34^+^43^+^ cells through the EHT in cocultures of hESCs and AGM-S3 cells, and that GATA2 is essential for the EHT during hematopoiesis.

GATA2 Overexpression Inhibits the Differentiation of 34^+^45^+^ HSPCs {#sec2.4}
---------------------------------------------------------------------

GATA2-OE increased production of CD34^high^CD45^+^ (34^high^45^+^) cells and inhibited production of 34^low^45^+^ and 34^--^45^+^ cells until day 16 of coculture ([Figures 4](#fig4){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}A). Flow cytometric analysis demonstrated that the percentages of cells positive for CD144, CD201, KDR, CD90, and CD105 were higher among 34^high^45^+^ cells than among 34^low^45^+^ and 34^--^45^+^ cells, whereas the percentages of cells positive for lineage-specific markers such as CD38, CD13, CD16, and CD14 were lower ([Figures 4](#fig4){ref-type="fig"}B and 4C). GATA2-OE increased production of 34^high^45^+^ cells and inhibited their differentiation into 34^low^45^+^ and 34^--^45^+^ cells ([Figures 4](#fig4){ref-type="fig"}A, 4B, and [S4](#mmc1){ref-type="supplementary-material"}A). GATA2-OE did not obviously change the immunophenotype of 34^high^45^+^ cells ([Figure 4](#fig4){ref-type="fig"}D). When Dox was removed from day 10, differentiation of 34^low^45^+^ and 34^--^45^+^ cells was restored on day 14 ([Figure 4](#fig4){ref-type="fig"}E). Thus, GATA2-OE promoted the generation of 34^high^45^+^ cells and inhibited their differentiation.Figure 4GATA2-OE Inhibits the Differentiation of CD34^+^CD45^+^ HSPCs(A) Absolute numbers of 34^high^45^+^, 34^low^45^+^, and 34^--^45^+^ cells in untreated and Dox-treated G2/hESC cocultures on days 2--16.(B) Flow cytometric analysis of 34^+^45^+^ cells in untreated and Dox-treated G2/hESCs co-cultures on day 14.(C) Flow cytometric analysis of the subphenotype of 34^high^45^+^, 34^low^45^+^, and 34^−^45^+^ cells in Dox-untreated G2/hESC cocultures on day 14.(D) Flow cytometric analysis of the subphenotype of 34^high^45^+^ cells in untreated and Dox-treated G2/hESC cocultures on day 14.(E) The percentage of 34^high^45^+^, 34^low^45^+^, and 34^--^45^+^ cells in untreated and Dox-treated G2/hESC cocultures on day 14.(F--J) Properties of 34^+^45^+^ cells sorted from G2/hESC cocultures on day 14. (F) Flow cytometric analysis of 34^+^45^+^ cells sorted from untreated and Dox-treated cocultures on day 14. (G) Western blotting and RT-qPCR analysis of GATA2 in 34^+^45^+^ cells sorted from untreated and Dox-treated cocultures on day 14. (H--I) Colony formation by 34^+^45^+^ cells sorted from untreated and Dox-treated cocultures on day 14. (J) β-Globin expression in BFU-E colonies derived from 34^+^45^+^ cells with and without Dox. Scale bars, 20 μm.Error bars represent mean ± SD of samples from at least three independent experiments. NS, not significant; ^∗^p \< 0.05, ^∗∗^p \< 0.01.

To further elucidate the effect of GATA2-OE on differentiation of 34^+^45^+^ cells, these cells were sorted from cocultures on day 14 ([Figure 4](#fig4){ref-type="fig"}F). Western blotting and qRT-PCR analysis demonstrated that *GATA2* expression was upregulated in 34^+^45^+^ cells sorted from Dox-treated cocultures ([Figure 4](#fig4){ref-type="fig"}G). Removal of Dox increased the numbers of BFU-E, Mix, GM, and M colonies, while GATA2-OE increased the number of G colonies ([Figures 4](#fig4){ref-type="fig"}H and 4I). More CD71^+^GPA^+^ erythroid cells were detected by FACS analysis when Dox was removed during the colony-formation assay ([Figure S4](#mmc1){ref-type="supplementary-material"}B). BFU-E formed from GATA2-overexpressing cocultured cells generated erythroid cells that predominantly expressed adult β-globin ([Figure 4](#fig4){ref-type="fig"}J). These data demonstrate that GATA2-OE inhibits the differentiation of hematopoietic cells.

To further investigate the effect of GATA2-OE on the differentiation of 34^+^45^+^ cells, we recultured 34^+^45^+^ cells on day 14 in IMDM containing 10% fetal bovine serum (FBS) and seven cytokines. More cells with a 34^--^45^+^ phenotype were produced in the presence of Dox ([Figures S4](#mmc1){ref-type="supplementary-material"}C and S4D). Upon suspension of cultures to induce differentiation, Dox treatment decreased the percentage of CD163^+^CD14^+^ cells (macrophages), but increased the percentages of c-KIT^+^CD45^+^ (mast cells) and Siglec-8^+^CD88^+^ cells (eosinophils) ([Figures S4](#mmc1){ref-type="supplementary-material"}C--S4E).

Thus, GATA2-OE increases production of 34^+^43^+^45^+^ cells, but prevents their differentiation in cocultures and the colony-formation assay. By contrast, GATA2-OE increases the granulocytic and mast cell potential of 34^+^45^+^ cells in suspension culture and the colony-formation assay.

GATA2 Overexpression Maintains HSPCs by Inducing Cell-Cycle Arrest {#sec2.5}
------------------------------------------------------------------

5′-Bromo-2′-deoxyuridine (BrdU) incorporation analysis suggestd that 34^+^45^--^ cells differentiated into 34^high^45^+^ cells, which was accompanied by a decreased percentage of cells in G0/G1 phase and an increased percentage of cells in S stage ([Figure 5](#fig5){ref-type="fig"}A). The cell cycle of 34^+^45^--^ cells did not obviously differ between untreated and Dox-treated cocultures at day 14 ([Figure 5](#fig5){ref-type="fig"}A). However, the cell cycle of 34^+^45^+^ cells differed between untreated and Dox-treated samples at day 14 of coculture and day 3 of suspension culture ([Figures 5](#fig5){ref-type="fig"}A--5D). The decreased generation of hematopoietic cells from 34^+^45^+^ cells on Dox treatment was due to induction of quiescence, while removal of Dox promoted progression of 34^+^45^+^ cells into S and G2/M phase ([Figures 5](#fig5){ref-type="fig"}B and 5D).Figure 5GATA2-OE Promotes the Maintenance and Inhibits the Differentiation of HSPCs by Inducing Cell-Cycle Arrest(A--D) Flow cytometric analysis and quantification of BrdU incorporation and 7-AAD staining to determine the cell-cycle distribution of (A and C) 34^+^45^+^ HSPCs on day 14 of coculture and (B and D) day 3 of suspension culture.(E--G) Gene expression profile of 34^+^K^+^43^--^ cells (E) on day 6 of coculture, and (F) 34^+^45^+^ cells on 14 of coculture and (G) day 3 of suspension culture.(H) Apoptosis detection of hematopoietic cells from G2/hESC cocultures on day14 with and without Dox through flow cytometric analysis.Error bars represent mean ± SD of samples from at least three independent experiments. NS, not significant; ^∗^p \< 0.05, ^∗∗^p \< 0.01.

Despite confirming GATA2-OE in 34^+^K^+^43^--^ and 34^+^45^+^ cells treated with Dox, qRT-PCR analysis demonstrated that the expression of cell-cycle-related genes was markedly altered in the latter cells ([Figures 5](#fig5){ref-type="fig"}E--5G). Expression of genes encoding cell-cycle activators, such as *CCND3*, *MCM5*, and *CEBPA*, was decreased in GATA2-OE 34^+^45^+^ cells. In addition, *AHRR* and *CYB1P1* expression were reduced in GATA2-OE 34^+^45^+^ cells ([Figures 5](#fig5){ref-type="fig"}F and 5G). On removal of Dox from suspension cultures, expression of *GATA2* decreased in 34^+^45^+^ cells, while that of *CD38* and *CYB1P1* increased ([Figure 5](#fig5){ref-type="fig"}G). Enforced GATA-2 expression showed no increase in apoptosis of coculture cells. GATA2-OE inhibited apoptosis in CD34^high^CD45^+^ cells on coculture day14 ([Figure 5](#fig5){ref-type="fig"}H). These data suggest that GATA2-OE prevents the expansion and differentiation of 34^+^45^+^ cells isolated from cocultures on day 14 by inducing quiescence and inhibiting apoptosis.

GATA2 Overexpression Selectively Promotes the Maintenance of 34^+^45^+^90^+^38^--^ HS-like Cells {#sec2.6}
------------------------------------------------------------------------------------------------

CD90^+^ cells were enriched among 34^high^45^+^ cells ([Figure 4](#fig4){ref-type="fig"}C). The percentages of cells positive for endothelial markers, such as CD201, KDR, CD144, and CD61, were higher among 34^+^45^+^90^+^38^--^ HS-like cells than among 34^+^45^+^90^--^38^--^ cells ([Figure 6](#fig6){ref-type="fig"}A). A two-step differentiation protocol was applied to develop HS-like cells from H1 hESC cocultures on day14 ([Figure 6](#fig6){ref-type="fig"}B). Medium was replaced by α-minimum essential medium containing 20% FBS, thrombopoietin, stem cell factor, and FMS-like tyrosine kinase 3 ligand (FL), which supports the maintenance of multipotent human HS-like cells ([Figure 6](#fig6){ref-type="fig"}B). To investigate the functional properties of GATA2-OE HS-like cells, 34^+^45^+^90^+^38^--^ HS-like cells were sorted and replated onto AGM-S3 cells ([Figure 6](#fig6){ref-type="fig"}C). Although 34^+^45^+^90^+^38^--^ cells were detected in the presence of Dox, the percentage of these cells rapidly decreased when Dox was removed ([Figures 6](#fig6){ref-type="fig"}D, 6E, and [S5](#mmc1){ref-type="supplementary-material"}A). To further elucidate the effect of GATA2-OE on differentiation of hematopoietic cells, cocultured cells on day 14 were cultured in differentiation medium and their ability to differentiate into CD34^+^CD45^+^CD38^+^ (34^+^45^+^38^+^) progenitors was investigated ([Figures 6](#fig6){ref-type="fig"}F and [S5](#mmc1){ref-type="supplementary-material"}B). The percentage of 34^+^45^+^38^+^ cells by FACS and relative expression of *CD38* in 34^+^45^+^ cells by qRT-PCR increased when Dox was removed ([Figures 5](#fig5){ref-type="fig"}G, [6](#fig6){ref-type="fig"}F, and [S5](#mmc1){ref-type="supplementary-material"}B).Figure 6GATA2-OE Selectively Promotes the Maintenance of 34^+^45^+^90^+^38^--^ HS-like Cells(A) Flow cytometric analysis of the subphenotype of 34^+^45^+^90^+^38^--^ and 34^+^45^+^90^--^38^--^ cells from Dox untreated G2/hESC cocultures on day 14.(B) Analysis of the maintenance of HS-like 34^+^45^+^90^+^38^--^ cells derived from H1 hESC cocultures on day 14. The absolute number of 34^+^45^+^90^+^38^--^ cells on day 14 + 7 is shown.(C) Flow cytometric analysis of 34^+^45^+^90^+^38^--^ HS-like cells sorted from untreated and Dox-treated G2/hESC cocultures on day 14.(D and E) Percentages and absolute numbers of (D) 34^+^45^+^90^+^38^--^ and (E) 34^+^45^+^90^--^38^--^ cells derived from sorted 34^+^45^+^90^+^38^--^ cells treated with and without Dox for 14 days.(F) Expansion of 34^+^45^+^38^+^ cells derived from untreated and Dox-treated G2/hESC cocultures on day 14 in medium containing FBS and cytokines.Error bars represent mean ± SD of samples from at least three independent experiments. NS, not significant; ^∗^p \< 0.05, ^∗∗^p \< 0.01.

GATA2-OE promoted the development and maintenance of 34^+^45^+^90^+^38^--^ HS-like cells and inhibited their differentiation into 34^+^45^+^38^+^ hematopoietic cells. These data show that GATA2 selectively promotes the development and maintenance of HS-like cells when expressed in the correct cellular context.

GATA2 Overexpression Maintains 34^+^45^+^90^+^38^--^ HS-like Cells by Regulating Expression of Cell-Cycle-Related Genes {#sec2.7}
-----------------------------------------------------------------------------------------------------------------------

To dissect the transcriptional features of 34^+^45^+^90^+^38^--^ HS-like cells, we isolated 34^+^45^+^90^+^38^--^ and 34^+^45^+^38^+^ cells from Dox-treated and -untreated G2/hESC cocultures and performed RNA-seq. Thereafter, we compared the transcriptional profiles of these cells with those of HSCs (CD34^+^CD38^−^CD90^+^CD45RA^−^) and progenitors (CD34^+^CD38^+^) derived from FL, CB, and bone marrow (BM) ([@bib4]).

Unsupervised hierarchical clustering of GATA2-OE 34 ^+^ 45^+^90 ^+^ 38^−^ cells (G2-OE 90^+^), 34 ^+^ 45^+^90 ^+^ 38^−^ cells (90^+^) and CD34^+^CD45^+^CD38^+^ cells (38^+^) showed that G2-OE 90^+^ and 90^+^ were positioned next to each other ([Figure 7](#fig7){ref-type="fig"}A).Figure 7GATA2-OE Maintains 34^+^45^+^90^+^38^--^ HS-like Cells by Regulating Expression of Cell-Cycle-Related Genes(A) Unsupervised hierarchical clustering of RNA-seq data of 34^+^45^+^38^+^ (38^+^), 34^+^45^+^90^+^38^--^ (90^+^) and G2-OE 34 ^+^ 45^+^90 ^+^ 38^−^ (G2-OE 90^+^) cells. RNA-seq of 38^+^, 90^+^, and G2-OE 90^+^ cells was performed on day 14 of G2/hESC cocultures. Data are from three representative experiments (GEO: [GSE122207](ncbi-geo:GSE122207){#intref0020}).(B) Heatmaps showing mesodermal, endothelial, HSC, and hematopoietic progenitor cell (HPC) genes that were differentially expressed in G2-OE 90^+^, 90^+^, and 38^+^ cells. The scale is log~2~ RPKM (reads per kilobase of transcript per million). The data are from three FACS experiments. The heatmaps showed significant differences in gene expression in 90^+^ and 38^+^ cells, p \< 0.05. Expression of sample genes previously reported to be regulators of mesodermal cells, endothelial cells, HSCs, and HPCs is shown. Expression profiles were investigated in HSCs and progenitor cells derived from FL, CB, and BM ([@bib4]).(C) Numbers of differentially expressed genes in G2-OE 90^+^ cells (fold change \>2, p \< 0.05).(D) qRT-PCR analysis of *GATA2* expression in 90^+^ cells and G2-OE 90^+^ cells.(E and F) (E) Gene ontology categories of biological processes and (F) KEGG signaling pathways that were significantly downregulated in G2-OE 90^+^ cells.(G and H) Gene set enrichment analysis of (G) the stem cell proliferation and differentiation and (H) positive regulation of mitotic cell-cycle genes were repressed in G2-OE 90^+^ cells.Error bars represent mean ± SD of samples from at least three independent experiments. NS, not significant; ^∗^p \< 0.05, ^∗∗^p \< 0.01.

Gene expression patterns of hematopoietic markers, cell surface markers and HSC regulators were very similar in 34 ^+^ 45^+^90 ^+^ 38^−^ cells, 34 ^+^ 45^+^38^+^ cells and that cells derived from FL, CB, and BM ([Figures 7](#fig7){ref-type="fig"}B and [S6](#mmc1){ref-type="supplementary-material"}A). Expression of mesodermal and endothelial genes was similar in 90^+^ cells and FL-derived HSCs ([Figure 7](#fig7){ref-type="fig"}B). Taken together, the profiling data suggest that 90^+^ cells generated *in vitro* are transcriptionally very similar to HSCs and are most similar to human FL-derived HSCs.

HSC-specific gene expression was similar in untreated and Dox-treated hESC-derived HS-like cells, suggesting that GATA2-OE did not affect the HSC properties of these cells ([Figure 7](#fig7){ref-type="fig"}B). We next assessed how GATA2-OE affects the proliferation and differentiation of 90^+^ cells. In total, 5,058 genes (3,744 downregulated and 1,314 upregulated) were significantly differentially expressed between G2-OE 90^+^ and 90^+^ cells (2.85-fold; [Figures 7](#fig7){ref-type="fig"}C and 7D). Repressed genes in G2-OE 90^+^ cells were mostly enriched in gene ontology categories related to cell adhesion, motility, migration, proliferation, and differentiation ([Figure 7](#fig7){ref-type="fig"}E). Kyoto Encyclopedia of Genes and Genome (KEGG) analysis suggestd that several pathways important for regulation of HSCs were downregulated in G2-OE 90^+^ cells ([Figure 7](#fig7){ref-type="fig"}F). Gene set enrichment analysis (GSEA) showed that the stem cell proliferation and differentiation genes were repressed in G2-OE 90^+^ cells ([Figures 7](#fig7){ref-type="fig"}G and [S6](#mmc1){ref-type="supplementary-material"}B). GSEA showed that the positive regulation of mitotic cell-cycle and apoptosis genes were repressed in G2-OE 90^+^ cells ([Figures 7](#fig7){ref-type="fig"}H and [S6](#mmc1){ref-type="supplementary-material"}C). Expression of genes related to the AHR signaling pathway, which was previously reported to be inhibited by SR1 ([@bib35]), was also inhibited in G2-OE 90^+^ cells ([Figure S6](#mmc1){ref-type="supplementary-material"}D).

Discussion {#sec3}
==========

The mechanism that controls the development and maturation of hPSC-derived HSCs during definitive hematopoiesis remains to be elucidated, and its characterization is hindered by the lack of a serial observation method. GATA2 is expressed in a spatial- and temporal-dependent manner during definitive hematopoiesis and is thus a good marker to monitor early hematopoiesis of hPSCs. Using a PB-based Tet-on system to monitor GATA2-OE at different stages of hematopoiesis, we found that GATA2 plays dual roles before and after the emergence of 34^+^43^+^45^+^ HSPCs during definitive hematopoiesis.

[@bib22] reported that GATA2-OE promotes the generation of mesodermal cells from mouse embryonic stem cells. Forced expression of GATA2 stimulates hematopoietic specification at the mesodermal stage in a cell-autonomous manner in *Xenopus* ([@bib24]). However, knockout of GATA2 in hESCs does not markedly affect specification of mesodermal and endothelial lineages before hematopoiesis ([@bib19]).

In our coculture system, GATA2-OE enhanced the generation of K^+^34^−^ cells, which further developed into K^+^34^+^ hemogenic cells, suggesting GATA2 may promote early mesoderm differentiation toward endothelium and hematopoiesis. The discrepancy in the effects of GATA2 knockout and our overexpression system in mesodermal development might be because of the differentiation conditions used, the transient nature of K^+^34^−^ mesodermal cells, and the level of GATA2. A culture system favoring mesoderm differentiation will be more suitable for clarifying it.

Analysis of definitive hematopoiesis in the AGM region in conditional GATA2-knockout mice demonstrated that GATA2 is essential for the EHT ([@bib33], [@bib13]). The EHT is markedly inhibited in GATA2^−/−^ hESCs, and this effect is rescued by GATA2 overexpression ([@bib19]). Consistently, in our coculture system, GATA2-OE-induced expansion of K^+^34^+^43^+^ cells followed by K^--^34^+^43^+^ cells. Definitive hematopoiesis-related genes, including *GATA1*, *RUNX1c*, and *SPI1*, were also upregulated in GATA2-OE 34^+^K^+^43^--^ cells. *RUNX1c* marked a subset of cells expressing CD34, a cell surface marker present on human AGM-derived HSCs ([@bib17]). *RUNX1c* tracked EHT in the hematopoiesis of hESCs, while transcription factor *GATA2*, *GATA1*, and *SPI1* abundantly expressed in RUNX1c^+^ cells compared with RUNX1c^−^ cells ([@bib31]). Thus, our data suggest that GATA2-OE enhances definitive hematopoiesis through the promotion of EHT with a conserved cooperation of these critical genes for definitive hematopoiesis.

The CD34^med^CD45^+^ fraction showed higherhematopoietic potential compared with CD34^low^CD45^+^ and CD34^−^CD45^+^ cells from hESCs ([@bib10]). In our coculture system, the 34^high^45^+^ cell subset expressed a low percentage of differentiation makers and resided more in G0/G1 stage than CD34^low^CD45^+^ and CD34^−^CD45^+^ cell subsets, reflecting the hematopoietic potential was enhanced in 34^high^45^+^ cell subset. Since maintenance of dormancy and recovery on stimulation are the most important characteristics for sustaining HSCs throughout life ([@bib30]), the quiescence of 34^high^45^+^ GATA2-OE HSPCs and recovery in full hematopoietic activity when released from Dox showed their HS-like properties. The results are consistent with the previous finding that GATA2 alters hematopoietic lineage specification and cell differentiation ([@bib14], [@bib15], [@bib46]). Besides, GATA2-OE promotes quiescence in human CB-HSCs, sacrificing their proliferation and performance in long-term culture-initiating cell assays ([@bib45]). Enforced expression of GATA2 also blocks proliferation and differentiation of murine BM cells ([@bib34]). GATA2 seems to elicit a critical dose-dependent effect on maintenance of HSCs during early and late hematopoiesis. A recent study demonstrated that pulsatile changes in GATA2 expression subtly regulated the generation of HSCs ([@bib12]). The mechanisms by which GATA2 regulates the generation and maintenance of HSCs at different developmental stages must be further elucidated.

Lin^−^CD34^+^CD43^+^CD45^+/−^CD90^+^CD38^--^ cells in cocultures of hESCs and OP9 cells were previously defined as multipotent definitive hematopoietic progenitors ([@bib38]). Recent studies showed that hESC-derived hematopoietic cells are very similar to human AGM- and FL-derived HSCs in terms of their gene profiles and immunophenotypes, and thus these cells are defined as HS-like cells ([@bib11], [@bib31]). In the current study, GATA2-OE selectively maintained 34^+^45^+^90^+^38^--^ HS-like cells in cocultures for 2 weeks and inhibited their differentiation into 34^+^45^+^38^+^ progenitor cells. RNA-seq demonstrated that the maintenance of hESC-derived HS-like cells on GATA2-OE was due to downregulation of stem cell proliferation, differentiation, cell-cycle, and apoptosis pathways. Phosphatidylinositol 3-kinase-Akt signaling, which maintains the properties of HSCs, were downregulated on GATA2-OE ([@bib18]). AHR antagonists such as SR1 promoted the expansion of human HSCs ([@bib3]). The downregulation of genes related to the AHR pathway in G2-OE 90^+^ cells suggests that GATA2 maintains HS-like cells by inhibiting AHR signaling.

AGM-derived stromal cells were reported to predominantly support definitive hematopoiesis of hESCs ([@bib20]). AGM-S3 cells induce maturation of immature embryonic yolk sac cells and para-aortic splanchnopleure cells into reconstituting HSCs ([@bib26]). In the present study, AGM-S3 cells provided an ideal microenvironment for maintenance of 34^+^45^+^90^+^38^--^ HS-like cells. However, we failed to detect long-term engraftment of these cells in immunodeficient mice (data not shown), suggesting that intrinsic maturity and exogenous factors are further required for gaining transplantable ability in hESC-derived HS-like cells.

We provide evidence that complex and subtle regulation of GATA2 is important for the development, expansion, and maintenance of hESC-derived HS-like cells. GATA2 plays two functionally distinct roles in the generation and expansion of HSCs in the AGM region and the proliferation of HSCs in adult BM in mice ([@bib21]). In our system, the dual effects GATA2-OE on promoting early hemogenic endothelial precursors (typically 34^+^43^+^45^--^ cells) through the EHT and later arresting 34^+^45^+^ cells in a quiescent stage by cell-cycle regulation provided new insight into its function in the maturation of hPSC definitive hematopoiesis. Although we lack evidence of the reconstitution potential of HS-like cells derived from cocultures, the similar gene expression profiles for GATA2-OE HS-like cells and human FL-derived HSCs suggest the possibility to achieve functional HSCs by manipulating GATA2 expression. Our findings should help to elucidate the mechanism controlling definitive hematopoiesis in humans by GATA2 regulation and may assist in future clinical applications.

Experimental Procedures {#sec4}
=======================

Maintenance of hESCs {#sec4.1}
--------------------

H1 hESCs were provided by Professor Tao Cheng and maintained on Matrigel-coated plates in mTeSR1 medium (STEMCELL Technologies). The cells were dissociated into clumps using ReLeSR (STEMCELL Technologies) every 4--5 days.

Establishment of G2/hESCs {#sec4.2}
-------------------------

H1 hESCs were seeded into a 24-well plate with 70%--90% confluent at the time of transfection. Plasmid DNA-lipid complexes (containing 0.5 μg of the PB-Tet-on-GFP-T2A-hGATA2 vector, and 0.5 μg of PB200PA vector containing catalytic component) were added to the cells per well and incubated for 2--4 days according to the manufacturer's description of lipofectamine 3000 (Invitrogen). Transfected cells were selected by culture in medium containing 1 μg/mL puromycin (Sigma). For single-cell culture, cells were dissociated into single cells with Accutase (Gibco) and maintained in mTeSR1 medium supplemented with Y27632 (Cayman). Puromycin-resistant clones were picked, and successful targeting was confirmed by western blotting, qRT-PCR (F1:5′-CAGCAAGGCTCGTTCCTGTTCA-3′, R1:5′-ATGAGTGGTCGGTTCTGCCCAT-3′) and PCR (F2: 5′GAGGAAGTCTTCTAACATGCGGT-3′, R2: 5′CCCTTCGTCTGACGTGGCAG-3′). To minimize variation owing to long-term selection, multiple stable cell lines were used and all experiments were repeated at least three times. The study was approved by the Ethics Committee of the Institute of Blood Transfusion, CAMS & PUMC.

Coculture of hESCs and AGM-S3 Cells {#sec4.3}
-----------------------------------

Approximately 50--60 clumps of hESCs, each of which contained 3--4 × 10^2^ cells, were seeded onto 2--3 ×10^5^ irradiated AGM-S3 cells in each well of a 6-well plate and cultured in hPSC maintenance medium. hESCs were differentiated into HSPCs as described previously ([@bib25]). The medium was changed every day.

Colony Assay {#sec4.4}
------------

Hematopoietic potential of cells was assessed by culture on methylcellulose (H4320, STEMCELL Technologies) supplemented with 1% penicillin/streptomycin (Invitrogen) and cytokines, which were described previously ([@bib23]). BFU-E, CFU-Mix, CFU-GM, CFU-G, and CFU-M colonies were assessed after 10--16 days.

Flow Cytometry and Cell Sorting {#sec4.5}
-------------------------------

Cocultured cells were dissociated with 0.25% trypsin-EDTA solution (Invitrogen) and filtered through a 70-μm nylon mesh to obtain a single-cell suspension. Flow cytometry was performed using a FACSCanto II system (BD Biosciences), and data were analyzed using FlowJo software (v.10.0.8.). Cell sorting was performed using a MoFlo Astrios High Speed Cell Sorter (Beckman Coulter). The antibodies used are presented in [Table S1](#mmc1){ref-type="supplementary-material"}.

Cell-Cycle Analysis {#sec4.6}
-------------------

Cells were treated with BrdU for 6 h, stained for surface antigens, and processed using an APC-BrdU Flow Kit (BD) according to the manufacturer\'s instructions.

Apoptosis Assays {#sec4.7}
----------------

Cells were detected by flow cytometry of cells stained according to the manufacturer\'s instructions with annexin V--APC and 7-AAD (BioLegend).

Statistical Analysis {#sec4.8}
--------------------

All data are presented as the mean ± SD. Statistical analyses were performed using the Student\'s t test. p \< 0.05 was considered significant.
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